Download biomedica product list
NT-proBNP at Dialysis Initiation-Predictor of Heart Disease Hospitalization
NT-proBNP at Dialysis Initiation-Predictor of Heart Disease Hospitalization: Patients with end-stage kidney disease (ESKD) face a cardiovascular (CV) death risk approximately 10 to 20 times higher than that of the general population. Cardiac biomarkers serve as a valuable tool to predict CV morbidity and mortality in asymptomatic individuals.
About NT-proBNP
N-terminal pro-BNP (NT-proBNP) is a biomarker released by the heart in response to ventricular stretch and stress. It is commonly used to diagnose and manage heart failure, as elevated levels indicate cardiac dysfunction. NT-proBNP levels can also provide prognostic information regarding cardiovascular risk and outcomes in various conditions, including coronary artery disease, sepsis, and in patients with end-stage kidney disease (1).
NT-proBNP at Dialysis Initiation-Predictor of Heart Disease Hospitalization
A study by Shimohata H. et al, investigated if NT-proBNP measurement at the initiation of dialysis therapy is useful to predict later hospitalization for ischemic heart disease (IHD). The results demonstrated that NT-proBNP measurement at the initiation of dialysis therapy is useful to predict later hospitalization for IHD .
NT-proBNP was measured with the ELISA assay from BIOMEDICA
NT-proBNP ELISA assay kit (cat. no. SK-1204)
EASY – simple 2 step protocol, can be run in every lab
CONVENIENT – high and low kit controls included
RELIABLE – validated according to international quality guidelines (see validation data )
TRUSTED – widely cited in 140 publications
Related Products:
Rat NT-proBNP ELISA (cat. no. BI-1204R)
BNP Fragment EIA (cat. no. 20852W)
Literature
- NT-pro BNP level at dialysis initiation is a useful biomarker for predicting hospitalization for ischemic heart disease. Shimohata H, Usui J, Tawara-Iida T, Ebihara I, Ishizu T, Maeda Y, Kobayashi H, Numajiri D, Kaneshige A, Sega M, Yamashita M, Ohgi K, Maruyama H, Takayasu M, Hirayama K, Kobayashi M, Yamagata K; Study Group of the Ibaraki Dialysis Initiation Cohort Study. Clin Exp Nephrol. 2024 May;28(5):457-464. doi: 10.1007/s10157-023-02442-x.
- Association of NT-proBNP and BNP With Future Clinical Outcomes in Patients With ESKD: A Systematic Review and Meta-analysis. Harrison TG, Shukalek CB, Hemmelgarn BR, Zarnke KB, Ronksley PE, Iragorri N, Graham MM, James MT. Am J Kidney Dis. 2020 Aug;76(2):233-247. doi: 10.1053/j.ajkd.2019.12.017. Epub 2020 May 6. PMID: 32387090.
Abstract
Background: Patients with end-stage kidney disease (ESKD) are at high risk of cardiovascular disease including stroke, heart failure, and ischemic heart disease (IHD). To prevent the occurrence and progression of CVD, a reliable prognostic cardiac biomarker is essential. We investigated the prognostic value of NT-proBNP for each incident type of CVD.
Methods: Male patients from the Ibaraki Dialysis Initiation Cohort (iDIC) study with preserved serum samples from dialysis initiation day (n = 212) were analyzed. Patients were classified into four groups according to quartiles of baseline NT-pro BNP levels. The relationship between NT-proBNP levels at the initiation of dialysis and the subsequent incidence of hospitalization events due to IHD, heart failure, and stroke was analyzed.
Results: The incidence rate for hospitalization due to IHD was significantly higher in the highest NT-proBNP category (Log rank p = 0.008); those of stroke and heart failure showed no significant differences among quartiles. Cox proportional hazards regression analysis revealed that serum NT-proBNT was the only prognostic factor for hospitalization for IHD after adjustment by major known IHD risk factors. (HR, 1.008; 95% confidence interval, 1.002-1.014; p = 0.01) The ROC curve analysis for the incidence of hospitalization due to IHD showed that NT-proBNP had an area under the curve (AUC) of 0.759 (95% CI 0.622-0.897; p = 0.004) at a cut-off value of 956.6 pg/mL.
Conclusion: NT-proBNP measurement at the initiation of dialysis therapy is useful to predict later hospitalization for IHD.